Hangzhou Bozhirui Biopharmaceutical

Hangzhou Bozhirui Biopharmaceutical is a wholly-owned subsidiary of BioRay Biopharmaceutical (formerly Hisun BioRay), a leading Chinese biopharmaceutical company focused on immunology and oncology. Originally established as the biologics division of Hisun Pharmaceutical, the company became a core part of the BioRay group following a major investment by PAG in 2019. Hangzhou Bozhirui operates a large-scale, GMP-compliant manufacturing facility in Hangzhou that supports the production of an extensive portfolio of biosimilars and innovative antibodies. Its commercialized products include Anbainuo (etanercept biosimilar), Anjianning (adalimumab biosimilar), Anbeitai (infliximab biosimilar), and Anbaixia (tocilizumab biosimilar). The company is a key player in the Chinese autoimmune market and is actively expanding its pipeline into innovative biologics and oncology treatments.